Nail Psoriasis (Investigational Adjunct)
Investigational adjunct for nail psoriasis; topical corticosteroids, intralesional steroid, and (for severe disease) systemic biologics remain evidence-based.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for nail psoriasis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Welche Evidenz existiert?
- Tier C (investigational). Anecdotal only. Evidence-based first-line management of nail psoriasis is topical corticosteroid (often with calcipotriene), intralesional triamcinolone for matrix or bed involvement (limited by pain), and for moderate-to-severe disease or when concurrent skin or joint psoriasis is present, systemic therapy — methotrexate, apremilast, or biologic agents (anti-TNF, anti-IL-17, anti-IL-23), all of which have FDA approval for psoriasis.
- Hauptrisiken
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Bleeding around the nail unit that may dislodge already loose nails
- Aeromonas or other bacterial infection of the nail bed and periungual tissue
- Permanent nail dystrophy or matrix injury
- Wer dies nicht in Betracht ziehen sollte
- Patients with concurrent skin or joint psoriasis (these need systemic therapy that will also treat nails)
- Patients who have not tried topical therapy under dermatology guidance
- Patients with active fungal nail infection (different management needed)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Was Sie Ihren Kliniker fragen sollten
- Has fungal nail infection been excluded by KOH preparation or culture?
- Do I have skin or joint psoriasis that warrants systemic therapy that would also treat my nails?
- Have I tried topical corticosteroid with or without calcipotriene?
- What is the published evidence base for leeches in nail psoriasis?
- What is the risk of permanent nail matrix injury from bites near the nail?
- How will success be measured — NAPSI score, photographs, both?
- Wann dringende medizinische Versorgung suchen
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Severe pain, swelling, or pus around a nail (possible paronychia or abscess)
- Spreading redness up the finger or hand
- New joint pain and swelling — possible psoriatic arthritis requiring systemic therapy
Was dies NICHT bedeutet
- It does not mean leech therapy is FDA-cleared for nail psoriasis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace topical, intralesional, or systemic therapy with FDA-approved psoriasis treatments.
- It does not stop the underlying immunologic process driving psoriasis.
- It does not address concurrent psoriatic arthritis, which needs systemic therapy.
- It does not have RCT evidence for nail psoriasis.
Sicherheits-Querverweise
Clinical Profile
- Category
- dermatological
- ICD-10
- L40.86, L40.0
- Safety tier
- high
Evidence Summary
Nail psoriasis affects up to half of patients with cutaneous psoriasis and a majority of those with psoriatic arthritis, presenting as pitting, onycholysis, subungual hyperkeratosis, and oil-drop discoloration. Evidence-based topical therapy includes high-potency corticosteroids, vitamin D analogs, and tazarotene applied to the proximal nail fold. Intralesional corticosteroid injection has supporting evidence for refractory disease. Severe nail psoriasis often warrants systemic therapy, especially biologics targeting IL-17 and IL-23, which produce superior nail outcomes versus methotrexate. No published controlled trials of hirudotherapy exist for nail psoriasis. The digital arteries and nail matrix make finger placement uniquely high-risk for ischemia and persistent bleeding.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Placement on the digit, nail matrix, or eponychium (ischemia and persistent bleeding risk)
- Raynaud phenomenon
- Diabetes with peripheral vascular involvement
- Active nail infection (paronychia, onychomycosis with bacterial superinfection)
- Severe psoriasis where systemic therapy is indicated (refer to dermatology)
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.